Yes, routine PSA screening is absolutely necessary after total prostatectomy and should be performed regularly for at least the first 5 years, then annually thereafter.
PSA monitoring is the cornerstone of post-prostatectomy surveillance and should be performed every 6-12 months for the first 5 years, then annually. 1, 2 This is not optional—PSA is the primary method for detecting biochemical recurrence, which precedes clinical progression and allows for potentially curative salvage therapy.
Why PSA Monitoring is Essential
After total prostatectomy, PSA should become undetectable (< 0.1 ng/mL) within 1-2 months because the prostate—the source of PSA—has been removed 1. Any detectable or rising PSA indicates either residual prostate tissue or cancer recurrence. Biochemical recurrence (BCR) is defined as PSA ≥ 0.2 ng/mL confirmed on two successive measurements 1, 3, 4.
The critical point: approximately 10-53% of patients will develop biochemical recurrence depending on their preoperative risk 1. Without PSA monitoring, these recurrences would go undetected until clinical progression occurs—at which point salvage options are limited and less effective.
Recommended Surveillance Schedule
First 5 years:
- PSA every 6-12 months 2
- First PSA should be checked 3-12 months post-surgery 1
- If PSA is detectable, repeat in 1-3 months to confirm elevation and calculate PSA doubling time 1
After 5 years:
- Annual PSA testing 2
- Can potentially discontinue after 20 years if PSA remains undetectable and patient has favorable pathologic features 5
What Makes PSA Monitoring So Valuable
Early detection enables salvage therapy: The evidence is clear that salvage radiation therapy works best when PSA is low. Studies show 6-year progression-free survival of 48% when salvage radiation is given at PSA < 0.5 ng/mL versus only 18% when PSA > 1.5 ng/mL 3. This window of opportunity is only captured through regular PSA monitoring.
PSA kinetics predict outcomes: Beyond just the absolute PSA value, the pattern of PSA rise provides crucial prognostic information 1:
- Late BCR (>24 months) with slow PSA doubling time (>6 months) suggests local recurrence—potentially curable with salvage radiation
- Early BCR (<24 months) with rapid PSA doubling time (<6 months) suggests distant metastases—requires systemic therapy
No other test can replace PSA: Digital rectal examination (DRE) and imaging studies are unnecessary in men with undetectable PSA 6, 7. Multiple studies confirm that no patient with undetectable PSA has local recurrence or distant metastases. Imaging only becomes useful once PSA rises significantly (typically > 5-10 ng/mL for conventional imaging) 1.
Common Pitfalls to Avoid
Don't wait too long to check PSA: The first PSA should be obtained within 3-12 months post-surgery 1. Waiting longer delays detection of persistent disease.
Don't ignore low-level detectable PSA: While the formal BCR definition is ≥ 0.2 ng/mL, ultrasensitive PSA assays can detect lower levels. If using ultrasensitive PSA, confirm a rising trend before initiating therapy 4. However, for patients at high risk for recurrence, consider early salvage therapy even at PSA < 0.2 ng/mL 4.
Don't assume PSA will stay undetectable forever: Even after 20 years of undetectable PSA, 2.3% of men can develop late recurrence 5. While the risk is low and no prostate cancer deaths occurred in this group, continued surveillance is reasonable for men with adverse pathologic features.
Don't order unnecessary imaging: Bone scans and CT scans have extremely low yield at low PSA levels. The probability of a positive bone scan is < 5% even at PSA levels of 40-45 ng/mL 1, 8. Reserve imaging for PSA > 10 ng/mL or rapidly rising PSA, or consider PSMA-PET for earlier detection at lower PSA levels 4.
Special Considerations
Persistent PSA (never undetectable): If PSA fails to become undetectable after surgery, this requires prompt evaluation for residual or metastatic disease 1. However, recent evidence suggests waiting at least 3 months post-surgery before concluding PSA is truly persistent, especially in men with pre-operative PSA > 20 ng/mL, as some may eventually reach undetectable levels with more time 9.
High-risk patients: Men with adverse pathologic features (positive margins, seminal vesicle invasion, extracapsular extension, high Gleason score) warrant closer monitoring as they have higher recurrence rates 8.
The Bottom Line
Routine PSA screening after total prostatectomy is not just necessary—it's the standard of care. 1, 2 The evidence overwhelmingly supports regular PSA monitoring as it enables early detection of recurrence when salvage therapy is most effective, provides prognostic information through PSA kinetics, and eliminates the need for more invasive or expensive surveillance methods. Any provider caring for post-prostatectomy patients must implement systematic PSA surveillance according to these guidelines.